holbox / Shutterstock.com
Very few members of Congress are informed about the trajectory of section 101 and instead lawmakers are looking at ‘trolls’ and other patent issues, according to a counsel at the Biotechnology Industry Organization (BIO).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AIPLA 2015; section 101; BIO; Biotechnology Industry Organization; Myriad; patents